2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors
The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R 1 , R 2 , R 3 , R 4 , R A , X 1 , and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.
1. A compound of formula (I) or a pharmaceutically acceptable derivative, solvate or salt thereof,
wherein
the X 1 -azol moiety is attached at the 5- or 6-position of the 2,3-dihydrobenzofuran moiety;
n is an integer from 0 to 2;
m is an integer from 0 to 3;
p is an integer from 0 to 2;
R 1 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 2 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 3 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 4 is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 ,
—CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
X 1 is independently selected from NR n , O and S;
R n is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 ,
—CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
A is a monocyclic or bicyclic heteroaromatic ring system having 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from O, S and N, and wherein the remaining ring atoms are carbon atoms;
R A is independently selected from H, halogen, CN, NO 2 , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —OR′, —CO—R′, —COO—R′, —CONH—R′, —NHCO—R′, —CON(R′) 2 , —NR′CO—R′, —NR′—CONR′, —NR′—COOR′, —S—R′, —SO—R′, —SO 2 —R′, —NHSO 2 —R′, —SO 2 NH—R′, —O—CO—NHR′, —O—CO—R′, —R″′—O—R′, —R″′—CO—R′, —R″′−NH—R′, —R″′—CONH—R′, —R″′—NHCO—R′, R′, —CONH-alkyl-O—R′, —CONH-alkyl-R′, —NHCO-alkyl-O—R′, —NHCO-alkyl-R′, CO—R″′-alkyl-R′, —CO—R″′-alkyl, N(R′) 2 , —NHR′, NH 2 , —S-alkyl-R′ and alkyl-R′;
—R′ is independently selected from H, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
—R″′— is independently selected from alkylene, haloalkylene, arylene, heteroarylene, cycloalkylene and heterocycloalkylene;
wherein any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more substituents R″, wherein R″ is in each case independently selected from C 1-4 -alkyl, halogen, C 1-4 -haloalkyl, OH, C 1-4 -alkoxy, C 1-4 -haloalkoxy, nitro, —NH 2 , —N(C 1-4 -alkyl) 2 , —NH(C 1-4 -alkyl), —NHCO(C 1-4 -alkyl), —CONH 2 , —CONH(C 1-4 -alkyl), —CO(C 1-4 -alkyl), —COH, —COO(C 1-4 -alkyl), —COOH and —CN, and
wherein A is not pyridine substituted by heterocycloalkyl and A is not a pyrazole substituted with —CONH 2 , and
wherein said pharmaceutically acceptable derivative is a compound of formula I wherein a carboxylic acid group is derivatized into an ester, a hydroxyl group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, or a hydroxyl group is derivatized into a phosphate ester.
2. A compound according to claim 1 , wherein
R 1 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH; and
R 2 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH,
or a pharmaceutically acceptable derivative, solvate or salt thereof.
3. A compound according to claim 1 , wherein n is 0 and m is 0, or a pharmaceutically acceptable solvate or salt thereof.
4. A compound according to claim 1 , wherein R 3 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH, or a pharmaceutically acceptable derivative, solvate or salt thereof.
5. A compound according to claim 1 , wherein R 3 is H, or a pharmaceutically acceptable derivative, solvate or salt thereof.
6. A compound according to claim 1 , wherein R 4 is independently selected from H, C 1-3 -alkyl, C 1-4 -haloalkyl, OH, —CONH 2 , —CONH—C 1-3 -alkyl, —CO—C 1-3 -alkyl, and —COO—C 1-3 -alkyl, or a pharmaceutically acceptable derivative, solvate or salt thereof.
7. A compound according to claim 1 , wherein R 4 is H, or a pharmaceutically acceptable derivative, solvate or salt thereof.
8. A compound according to claim 1 , wherein
A is a monocyclic heteroaromatic ring system having 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system having 9 ring atoms,
wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms or one further ring atom is an O or S atom, or one further ring atom is an N atom and one ring atom is an O or S atom, and wherein the remaining ring atoms are carbon atoms, and
wherein A is optionally substituted with one or two substituents R A selected from H, CN, NO 2 , NH 2 , N(alkyl) 2 , halogen, OH, alkoxy, haloalkyl, alkyl, haloalkoxy, alkoxyalkyl, heterocycloalkyl, -heterocycloalkyl-alkyl, -heterocycloalkyl-COO-alkyl, heteroaryl, —COOH, —COO-alkyl, aralkyl, aryl, -aryl-halogen, —CO—N(alkyl) 2 , —CONH-(alkyl), —CONH-alkyl-alkoxy, —CONH-cycloalkyl, —CONH-alkyl-heterocycloalkyl, —CO-heterocycloalkyl-alkyl-heterocycloalkyl, —CO-heterocycloalkyl, —CO-heteroaryl, —CO-aryl, —CO-alkyl, —SO 2 -alkyl, —S-alkyl, —S-alkyl-COO—C 1-4 -alkyl and —S-aralkyl,
or a pharmaceutically acceptable derivative, solvate or salt thereof.
9. A compound according to claim 1 , wherein A is selected from thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole,
wherein A is optionally substituted with a substituent R A selected from H, CN, F, Cl, Br, OH, C 1-2 -alkyl, C 1-2 -alkoxy, CF 3 , OCF 3 , —COOH, —COO—(C 1-2 -alkyl), benzyl, phenethyl, phenyl, fluorophenyl, —CO—N(C 1-2 -alkyl) 2 , —CONH—(C 1-2 -alkyl), —CONH—(C 1-2 -alkyl)-O(C 1 2-alkyl), —CONH—(C 3-5 -cycloalkyl), —CONH—(C 1-2 -alkyl-tetrahydrofuryl), —CO-piperazinyl-(C 1-2 -alkyl)-tetrahydrofuranyl, —CO-morpholinyl, —CO-pyrrolidinyl, —CO-(methyl-piperazinyl)-, —SO 2 (C 1-2 -alkyl), —S—(C 1-4 -alkyl), —S-benzyl, —S-(chlorophenylmethyl), —S-phenethyl, —CO-thienyl, —CO— pyrrolyl, —CO-piperidinyl, —CO-piperidinyl-COO—(C 1-2 -alkyl), morpholinyl, C 1-2 -alkylpiperazinyl, C 1-2 -alkylthiazolyl, pyridyl, —CO-phenyl, —S—(C 1-2 -alkyl)-COO—(C 1-2 -alkyl), NH 2 , N(C 1-2 -alkyl) 2 , —CO—C 1-2 -alkyl, and —(C 1-2 -alkyl)-O(C 1-2 -alkyl),
wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and
wherein, when A is thiazole, A may optionally further be substituted with a methyl group,
or a pharmaceutically acceptable derivative, solvate or salt thereof.
10. A compound according to claim 1 , wherein the X 1 -azol moiety is attached at the 5-position of the 2,3-dihydrobenzofuran moiety.
11. A compound according to claim 1 , wherein the X 1 -azol moiety is attached at the 5-position of the 2,3-dihydrobenzofuran moiety;
n is 0 or 1;
m is 0 or 1;
X 1 is independently selected from NR n , O and S;
R n is independently selected from H, methyl, ethyl, OH, —CONH 2 , —CONH-methyl, and —COO— methyl;
R 1 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH;
R 2 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH;
R 3 is independently selected from H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, and —COOH;
R 4 is independently selected from H, C 1-3 -alkyl, C 1-4 -haloalkyl, OH, —CONH 2 , —CONH—C 1-3 -alkyl, —CO—C 1-3 -alkyl, and —COO—C 1-3 -alkyl;
A is independently selected from thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole;
wherein A is optionally substituted with a substituent R A selected from H, CN, F, Cl, Br, OH, C 1-2 -alkyl, C 1-2 -alkoxy, CF 3 , OCF 3 , —COOH, —COO—(C 1-2 -alkyl), benzyl, phenethyl, phenyl, fluorophenyl, —CO—N(C 1-2 -alkyl) 2 , —CONH—(C 1-2 -alkyl), —CONH—(C 1-2 -alkyl)-O(C 1-2 -alkyl), —CONH—(C 3-5 -cycloalkyl), —CONH—(C 1-2 -alkyl-tetrahydrofuryl), —CO-piperazinyl-(C 1-2 -alkyl)-tetrahydrofuranyl, —CO-morpholinyl, —CO-pyrrolidinyl, —CO-(methyl-piperazinyl)-, —SO 2 (C 1-2 -alkyl), —S—(C 1-4 -alkyl), —S-benzyl, —S-(chlorophenylmethyl), —S— phenethyl, —CO-thienyl, —CO-pyrrolyl, —CO-piperidinyl, —CO-piperidinyl-COO—(C 1-2 -alkyl), morpholinyl, C 1-2 -alkylpiperazinyl, C 1-2 -alkylthiazolyl, pyridyl, —CO-phenyl, —S—(C 1-2 -alkyl)-COO—(C 1-2 -alkyl), NH 2 , N(C 1-2 -alkyl) 2 , —CO—C 1-2 -alkyl, and —(C 1-2 -alkyl)-O(C 1-2 -alkyl);
wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and
wherein, when A is thiazole, A may optionally further be substituted with a methyl group;
or a pharmaceutically acceptable derivative, solvate or salt thereof.
12. A compound according to claim 1 , wherein the X 1 -azol moiety is attached at the 5-position of the 2,3-dihydrobenzofuran moiety;
n is 0;
m is 0;
X 1 is S,
R 3 is H;
R 4 is H;
A is a monocyclic or bicyclic heteroaromatic ring system selected from 1H-imidazol-2-yl, 1H-1,2,4-triazol-5-yl, 1H-benzo[d]imidazol-2-yl, pyridin-2-yl, 1,3,4-thiadiazol-2-yl, 1H-pyrazol-3-yl, 1,3-thiazol-2-yl, and 1,2,4-thiadiazol-3-yl;
wherein A is optionally substituted with a substituent R A selected from F, Cl, Br, CN, methyl, —SO 2 -Me, OMe, CF 3 , —CO—N(Me) 2 , 5-(4-((tetrahydrofuran-2-yl)methyl)piperazine-1-carbonyl, —COO-Et, morpholine-4-carbonyl, OCF 3 , —COO-Me, OH, —CO—NHMe, —S-Me, pyrrolidin-1-carbonyl, —CO—NH—C 2 H 4 —OMe, —S-iPr, cyclopropylcarbamoyl, 4-methylpiperazine-1-carbonyl, —S-nPr, COOH, —S-benzyl, —S-(4-chlorobenzyl), —S-iBu, ((tetrahydrofuran-2-yl)methyl)carbamoyl, phenethyl, —S-phenethyl, —CO-thien-2-yl, —CO-pyrrol-2-yl, —CO-piperidin-1-yl, —CO-(4-ethoxycarbonyl-piperidin-1-yl), morpholin-4-yl, 4-methyl-piperazin-1-yl, 5-methyl-thiazol-2-yl, pyridin-4-yl, —CO— phenyl, —S—(CH 2 )—COOMe, NH 2 , —CO—C 1-2 -alkyl, 3-fluorophenyl, acetyl, -methylthio, and methoxymethyl;
wherein, when A is 1H-benzo[d]imidazol-2-yl, A may optionally further be substituted with a chlorine atom, and
when A is 1,3-thiazol-2-yl, A may optionally further be substituted with a methyl group;
or a pharmaceutically acceptable derivative, solvate or salt thereof.
13. A compound according to claim 1 , wherein said compound is selected from the following compounds:
No.
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
and pharmaceutically acceptable derivatives, solvates and salts thereof.
14. A method of treatment of a medical condition selected from cancer of the breast, esophagus, gastrointestinal tract, gastro-intestinal stromal tumors, pancreas, prostate, biliary tract, bladder, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, glioma, small-cell lung cancer, oral squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, osteosarcoma, glioblastoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, acute myeloid leukemia, ovarian cancer, meningioma, and liver cancer, said method comprising:
administering an effective amount of a compound according to claim 13 to a subject in need thereof and wherein said treatment involves alleviation of said condition, stop of progression of said condition, or partial healing of said condition.
15. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.
16. A method of treatment of a medical condition selected from cancer of the breast, esophagus, gastrointestinal tract, gastro-intestinal stromal tumors, pancreas, prostate, biliary tract, bladder, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, glioma, small-cell lung cancer, oral squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, osteosarcoma, glioblastoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, acute myeloid leukemia, ovarian cancer, meningioma, and liver cancer, said method comprising:
administering an effective amount of a compound according to claim 1 to a subject in need thereof and wherein said treatment involves alleviation of said condition, stop of progression of said condition, or partial healing of said condition.
17. A method according to claim 16 , wherein said medical condition is pancreatic cancer.
18. A compound according to claim 1 , wherein X 1 is S, R 3 is H, R 4 is H.
19. A compound according to claim 1 , wherein X 1 is NR n .
20. A compound according to claim 1 , wherein X 1 is O.
21. A compound according to claim 1 , wherein X 1 is S.
22. A compound according to claim 1 , wherein A is thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyrimidine, thiadiazole, oxadiazole, or pyridine.
23. A compound according to claim 22 , wherein A is thiazol-2-yl, oxazol-2-yl, pyrazol-2-yl, pyrrol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, imidazol-2-yl, triazol-5-yl, pyrazin-2-yl, triazin-2-yl, pyrimidin-2-yl, thiadiazol-2-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-2-yl, oxadiazol-3-yl, oxadiazol-5-yl, or pyridin-2-yl.
24. A compound according to claim 22 , wherein A is 1H-imidazol-2-yl, 1H-1,2,4-triazol-5-yl, 1H-benzo[d]imidazol-2-yl, pyridin-2-yl, 1,3,4-thiadiazol-2-yl, 1H-pyrazol-3-yl, 1,3-thiazol-2-yl, 1,2,4-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1,3-oxazol-2-yl or 1,2,4-oxadiazol-3-yl.
25. A compound according to claim 22 , wherein A is thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, triazole, pyrazine, triazine, pyrimidine, thiadiazole, oxadiazole, or pyridine.
26. A compound according to claim 25 , wherein A is oxazol-2-yl, pyrazol-2-yl, pyrrol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, triazol-5-yl, pyrazin-2-yl, triazin-2-yl, pyrimidin-2-yl, thiadiazol-2-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-2-yl, oxadiazol-3-yl, oxadiazol-5-yl, or pyridin-2-yl.
27. A compound according to claim 25 , wherein A is 1H-1,2,4-triazol-5-yl, 1H-benzo[d]imidazol-2-yl, pyridin-2-yl, 1,3,4-thiadiazol-2-yl, 1,3-thiazol-2-yl, 1,2,4-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 1,3-oxazol-2-yl or 1,2,4-oxadiazol-3-yl.
28. A compound according to claim 1 , wherein
R 1 is, in each case independently, H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, or —COOH;
R 2 is, in each case independently, H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO-methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, or —COOH;
R 3 is, in each case independently, H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, —OCF 3 , OH, methoxy, ethoxy, —CN, nitro, —NH 2 , —N(methyl) 2 , —NH-methyl, —NHCO— methyl, —CONH 2 , —CONH-methyl, acetyl, —COO-methyl, or —COOH; and
R 4 is, in each case independently, H, C 1-3 -alkyl, C 1-4 -haloalkyl, OH, —CONH 2 , —CONH—C 1-3 -alkyl, —CO—C 1-3 -alkyl, or —COO—C 1-3 -alkyl.
29. A compound according to claim 28 , wherein
R A is, in each case independently, H, CN, F, Cl, Br, OH, C 1-2 -alkyl, C 1-2 -alkoxy, CF 3 , OCF 3 , —COOH, —COO—(C 1-2 -alkyl), benzyl, phenethyl, phenyl, fluorophenyl, —CO—N(C 1-2 -alkyl) 2 , —CONH—(C 1-2 -alkyl), —CONH—(C 1-2 -alkyl)-O(C 1-2 -alkyl), —CONH—(C 3-5 -cycloalkyl), —CONH—(C 1-2 -alkyl-tetrahydrofuryl), —CO-piperazinyl-(C 1-2 -alkyl)-tetrahydrofuranyl, —CO— morpholinyl, —CO-pyrrolidinyl, —CO-(methyl-piperazinyl)-, —SO 2 (C 1-2 -alkyl), —S—(C 1-4 -alkyl), —S-benzyl, —S-(chlorophenylmethyl), —S-phenethyl, —CO-thienyl, —CO-pyrrolyl, —CO-piperidinyl, —CO-piperidinyl-COO—(C 1-2 -alkyl), morpholinyl, C 1-2 -alkylpiperazinyl, C 1-2 -alkylthiazolyl, pyridyl, —CO-phenyl, —S—(C 1-2 -alkyl)-COO—(C 1-2 -alkyl), NH 2 , N(C 1-2 -alkyl) 2 , —CO—C 1-2 -alkyl, or —(C 1-2 -alkyl)-O(C 1-2 -alkyl).
30. A compound according to claim 29 , wherein A is thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyrimidine, thiadiazole, oxadiazole, or pyridine.
31. A compound according to claim 30 , wherein A is oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, triazole, pyrazine, triazine, pyrimidine, thiadiazole, oxadiazole, or pyridine.
32. A compound according to claim 28 , wherein R 1 , R 2 , R 3 , and R 4 are each H.
33. A compound according to claim 29 , wherein R 1 , R 2 , R 3 , and R 4 are each H.
34. A compound according to claim 32 , wherein X 1 is S.
35. A compound according to claim 33 , wherein X 1 is S.
36. A compound of formula (I) or a pharmaceutically acceptable derivative, solvate or salt thereof,
wherein
the X 1 -azol moiety is attached at the 5- or 6-position of the 2,3-dihydrobenzofuran moiety;
n is an integer from 0 to 2;
m is an integer from 0 to 3;
p is an integer from 0 to 2;
R 1 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 2 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 3 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 4 is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 ,
—CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
X 1 is independently selected from NR n , O and S;
R n is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 , —CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
A is a monocyclic or bicyclic heteroaromatic ring system having 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from O, S and N, and wherein the remaining ring atoms are carbon atoms;
R A is independently selected from H, halogen, CN, NO 2 , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —OR′, —CO—R′, —COO—R′, —CONH—R′, —NHCO—R′, —CON(R′) 2 , —NR′CO—R′, —NR′—CONR′, —NR′—COOR′, —S—R′, —SO—R′, —SO 2 —R′, —NHSO 2 —R′, —SO 2 NH—R′, —O—CO—NHR′, —O—CO—R′, —R″′—O—R′, —R″′—CO—R′, —R″′—NH—R′, —R″′—CONH—R′, —R″′—NHCO—R′, —CONH-alkyl-O—R′, —CONH-alkyl-R′, —NHCO-alkyl-O—R′, —NHCO-alkyl-R′, CO—R″′-alkyl-R′, —CO—R″′-alkyl, N(R′) 2 , —NHR′, NH 2 , —S-alkyl-R′ and alkyl-R′;
—R′ is independently selected from H, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
—R″′— is independently selected from alkylene, haloalkylene, arylene, heteroarylene, cycloalkylene and heterocycloalkylene;
wherein any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more substituents R″, wherein R″ is in each case independently selected from C 1-4 -alkyl, halogen, C 1-4 -haloalkyl, OH, C 1-4 -alkoxy, C 1-4 -haloalkoxy, nitro, —NH 2 , —N(C 1-4 -alkyl) 2 , —NH(C 1-4 -alkyl), —NHCO(C 1-4 -alkyl), —CONH 2 , —CONH(C 1-4 -alkyl), —CO(C 1-4 -alkyl), —COH, —COO(C 1-4 -alkyl), —COOH and —CN, and
wherein A is not pyridine substituted by heterocycloalkyl and A is not pyrazole, and
wherein said pharmaceutically acceptable derivative is a compound of formula I wherein a carboxylic acid group is derivatized into an ester, a hydroxyl group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, or a hydroxyl group is derivatized into a phosphate ester.
37. A compound of formula (I) or a pharmaceutically acceptable derivative, solvate or salt thereof,
wherein
the X 1 -azol moiety is attached at the 5- or 6-position of the 2,3-dihydrobenzofuran moiety;
n is an integer from 0 to 2;
m is an integer from 0 to 3;
p is an integer from 0 to 2;
R 1 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 2 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 3 is independently selected from H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, —CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —S—R′, —SO—R′, nitro, —NH 2 , —N(R′) 2 , —NH(R′), —NHCO(R′), —CONH 2 , —CONH(R′), —CO(R′), —COH, —COO(R′), —COOH, —SO 2 NH 2 , —SO 2 NH(R′), —SO 2 (R′), —NH—SO 2 (R′) and —NHCOOR′;
R 4 is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 ,
—CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
X 1 is independently selected from NR n , O and S;
R n is independently selected from H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CONH 2 ,
—CONH(R′), —CO(R′), —COO(R′), and —SO 2 (R′);
A is a monocyclic or bicyclic heteroaromatic ring system having 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from O, S and N, and wherein the remaining ring atoms are carbon atoms;
R A is independently selected from H, halogen, CN, NO 2 , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —OR′, —CO—R′, —COO—R′, —NHCO—R′, —CON(R′) 2 , —NR′CO—R′, —NR′—CONR′, —NR′—COOR′, —S—R′, —SO—R′, —SO 2 —R′, —NHSO 2 —R′, —SO 2 NH—R′, —O—CO—NHR′, —O—CO—R′, —R″′—O—R′, —R″′—CO—R′, —R″′—NH—R′, —R″′—CONH—R′, —R″′—NHCO—R′, —CONH-alkyl-O—R′, —CONH-alkyl-R′, —NHCO-alkyl-O—R′, —NHCO-alkyl-R′, CO—R″′-alkyl-R′, —CO—R″′-alkyl, N(R′) 2 , —NHR′, NH 2 , —S-alkyl-R′ and alkyl-R′;
—R′ is independently selected from H, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
—R″′— is independently selected from alkylene, haloalkylene, arylene, heteroarylene, cycloalkylene and heterocycloalkylene;
wherein any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more substituents R″, wherein R″ is in each case independently selected from C 1-4 -alkyl, halogen, C 1-4 -haloalkyl, OH, C 1-4 -alkoxy, C 1-4 -haloalkoxy, nitro, —NH 2 , —N(C 1-4 -alkyl) 2 , —NH(C 1-4 -alkyl), —NHCO(C 1-4 -alkyl), —CONH 2 , —CONH(C 1-4 -alkyl), —CO(C 1-4 -alkyl), —COH, —COO(C 1-4 -alkyl), —COOH and —CN, and
wherein A is not pyridine substituted by heterocycloalkyl and A is not a pyrazole substituted with —CONH 2 , and
wherein said pharmaceutically acceptable derivative is a compound of formula I wherein a carboxylic acid group is derivatized into an ester, a hydroxyl group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, or a hydroxyl group is derivatized into a phosphate ester.
38. A method of treatment of a medical condition selected from cancer of the breast, esophagus, gastrointestinal tract, gastro-intestinal stromal tumors, pancreas, prostate, biliary tract, bladder, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, glioma, small-cell lung cancer, oral squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, osteosarcoma, glioblastoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, acute myeloid leukemia, ovarian cancer, meningioma, and liver cancer, said method comprising:
administering an effective amount of a compound according to claim 36 to a subject in need thereof and wherein said treatment involves alleviation of said condition, stop of progression of said condition, or partial healing of said condition.
39. A method of treatment of a medical condition selected from cancer of the breast, esophagus, gastrointestinal tract, gastro-intestinal stromal tumors, pancreas, prostate, biliary tract, bladder, basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, glioma, small-cell lung cancer, oral squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, osteosarcoma, glioblastoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, acute myeloid leukemia, ovarian cancer, meningioma, and liver cancer, said method comprising:
administering an effective amount of a compound according to claim 37 to a subject in need thereof and wherein said treatment involves alleviation of said condition, stop of progression of said condition, or partial healing of said condition.